Glaukos Corp Asset Resilience Ratio

Latest as of March 2026: 19.30%

Glaukos Corp asset resilience ratio. Glaukos Corp (GKOS) has an Asset Resilience Ratio of 19.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Glaukos Corp defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$172.44 Million
Cash + Short-term Investments

Total Assets

$893.33 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Glaukos Corp (2013–2025)

Asset resilience ratio of Glaukos Corp from 2013 to 2025. This chart shows how Glaukos Corp's Asset Resilience Ratio has changed over time. Read GKOS total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Glaukos Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Glaukos Corp balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $172.44 Million 19.3%
Total Liquid Assets $172.44 Million 19.30%

Asset Resilience Insights

  • Good Liquidity Position: Glaukos Corp maintains a healthy 19.30% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Glaukos Corp Industry Peers by Asset Resilience Ratio

Compare Glaukos Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Ningbo David Medical Device Co Ltd
SHE:300314
Medical Devices 5.11%
Affluent Medical SAS
PA:AFME
Medical Devices 0.03%
MODULIGHT OY EO 1
F:78W
Medical Devices 15.99%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%
Nova EYE Medical Ltd
AU:EYE
Medical Devices 11.08%
Promimic AB
ST:PRO
Medical Devices 8.62%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%

Glaukos Corp Asset Resilience Ratio by Year (2013–2025)

Glaukos Corp asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Glaukos Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 21.04% $187.95 Million $893.49 Million +5.72pp
2024-12-31 15.32% $149.29 Million $974.76 Million -6.16pp
2023-12-31 21.48% $201.96 Million $940.41 Million -0.23pp
2022-12-31 21.71% $233.17 Million $1.07 Billion -6.05pp
2021-12-31 27.76% $313.34 Million $1.13 Billion -2.85pp
2020-12-31 30.61% $307.77 Million $1.01 Billion +16.98pp
2019-12-31 13.63% $111.55 Million $818.40 Million -39.84pp
2018-12-31 53.47% $110.67 Million $206.97 Million -3.52pp
2017-12-31 56.99% $94.51 Million $165.84 Million -9.45pp
2016-12-31 66.43% $89.27 Million $134.37 Million +6.82pp
2015-12-31 59.62% $69.55 Million $116.66 Million +59.39pp
2014-12-31 0.23% $60.00K $26.02 Million +0.04pp
2013-12-31 0.19% $60.00K $30.88 Million --
pp = percentage points

About Glaukos Corp

NYSE:GKOS USA Medical Devices
Market Cap
$12.92 Billion
Market Cap Rank
#2573 Global
#943 in USA
Share Price
$219.98
Change (1 day)
-10.83%
52-Week Range
$83.86 - $246.70
All Time High
$246.70
About

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more